A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Key Inclusion Criteria:

1. Study eye with diagnosis of GA of the macula secondary to AMD as described in theprotocol

2. Total GA area in the study eye measuring between ≥2.5 mm^2 and ≤17.5 mm^2 asdescribed in the protocol

3. BCVA of 55 letters or better using ETDRS charts (20/80 Snellen equivalent) in thestudy eye as described in the protocol

4. Sufficiently clear ocular media, adequate pupillary dilation and fixation to permitquality fundus imaging in the study eye as described in the protocol

5. Willing and able to comply with clinic visits and study-related procedures,including completion of the full series of meningococcal vaccinations andpneumococcal vaccination required per protocol

Key Exclusion Criteria:

1. GA in either eye due to causes other than AMD, such as Stargardt disease, cone roddystrophy or toxic maculopathies like hydroxychloroquine maculopathy

2. History or current evidence of Macular Neovascularization (MNV) and/or exudation orPeripapillary Choroidal Neovascularization (PPCNV) in either eye as described in theprotocol

3. Prior or current Intravitreal (IVT) treatment of any kind for any indication instudy eye or fellow eye, except approved or investigational IVT complement inhibitortherapy or anti-VEGF therapy, as long as last dose was ≥6 months prior torandomization

4. Prior intraocular surgery except cataract extraction or minimally invasive glaucomasurgery in study eye as long as date of these procedures was ≥3 months prior torandomization

5. Comorbid progressive ocular condition (eg, diabetic retinopathy, macular edema,uncontrolled glaucoma, full thickness macular hole) in study eye that could affectcentral vision and confound study

6. Any ophthalmologic condition that reduces the clarity of the media and that, in theopinion of the investigator interferes with ophthalmologic examination of the studyeye (e.g., advanced cataract or corneal abnormalities) as described in the protocol Systemic Exclusion criteria

7. History or current use of systemic complement inhibitor therapy within 6 monthsprior to randomization as described in the protocol

8. History of solid organ or bone marrow transplantation

9. Use of chronic (>14 days) systemic corticosteroids (oral or parenteral, ≥20 mg oralprednisone or equivalent) within the previous 30 days prior to the first screeningvisit as described in the protocol

10. Current or prior use of systemic immunosuppressive therapy other thancorticosteroids within 12 months prior to randomization or the likelihood oftreatment with any such agent during the study inclusive of the screening period asdescribed in the protocol

11. Not meeting meningococcal or pneumococcal vaccination requirements as described inthe protocol

12. Carrier of Neisseria meningitidis based on culture collected during screening

13. Has a hemoglobin A1C ≥ 8.0% during screening as described in the protocol

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply